| |
 |
Vioptix
Applications |
 |
 |
 |
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
Manifestations
of PVD |
 |
 |
 |
 |
 |

PVC FACTS: Over
10 million Americans affected in the US, growing at 5%/yr.
Affects
20% of the elderly (>70 y.o) and 40% of Diabetics
Grossly underdiagnosed: 71% of Physicians overlook condition
in their patients Patients
with PVD are 4 times more likely to have an infarct and 3 times
more likely to have a stroke. 5-yr
mortality: 30% (Compared with 18% for Hodgkin’s and 15%
for Breast Ca) |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
PORH
StO2 Curve |
 |
 |
 |
 |
 |

enlarge
|
 |
 |
 |
 |
 |
 |
 |
|
|
PERIPHERAL
VASCULAR DISEASE - PVD
PVD is a common circulatory disease in which the arteries that
carry blood to the legs or arms become narrowed or clogged. The
most common cause is atherosclerosis, or hardening of the arteries.
The disease causes compromised blood flow, which manifests as claudication
(leg pain after exercise). It may be acutely compounded by either
emboli or thrombi, and patients are at higher risk for heart disease
and stroke. In advanced cases, the patient may feel burning or aching
pain in the foot and toes while resting, and ulcers may develop.
Untreated PVD can lead to gangrene, a serious condition that may
require amputation of a leg, foot or toes. PVD is a chronic, progressive
and debilitating disease of nearly pandemic proportion. Risk factors
for PVD include high cholesterol, hypertension, diabetes, smoking,
obesity or history of cardiovascular disease.
Statistics:
• It is estimated that PVD affects 10 million patients in
the US
• Incidence is expected to increase significantly over the
next several years as the population ages.
• Between 20 and 30 per cent of patients over 60 years of
age have PVD.
• Approximately 30 per cent of patients will ultimately require
open surgical or percutaneous revascularization. The five-year mortality
rate for patients with PVD approaches 30 per cent
• Life expectancy of PVD patients is reduced by 10 years
Clinical Value:
The ODISsey Tissue Oximeter takes direct measurement of tissue oxygen
saturation levels in real time. It is easy for physicians to use
and provides a quick, reliable measurement, non-invasively. The
Company expects ODISsey to quickly become the standard of care for
screening, diagnosing and monitoring PVD patients.
Note: Some of the applications discussed in the Application and
Future Applications section are for research purposes only.
|
|